Literature DB >> 7623727

Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy.

F M Fink1, N Genser, C Fink, M Falk, J Mair, K Maurer-Dengg, I Hammerer, B Puschendorf.   

Abstract

Anthracyclines (doxorubicin, daunorubicin, and derivatives) are among the most effective antineoplastic drugs for pediatric cancer with dose-limiting acute and long-term cardiotoxicity. The exact mechanism of the development of cardiomyopathy is still not clear. Anthracyclines may induce subclinical acute myocardial injury leading to lysis of a limited number of myocytes. Alternatively, myocytes may experience a transient loss of cytoplasmic membrane integrity. Both conditions may lead to a transient efflux of small amounts of cytoplasmic enzymes and other proteins specific to the heart muscle fibers. To test these hypotheses we assayed plasma creatine kinase (CK) MB mass and cardiac specific troponin T (TnT). CKMB may be released even in case of reversible cell membrane injury, while prolonged elevation of TnT is the most sensitive and specific marker of limited myocardial necrosis. Thirty-five anthracycline-containing chemotherapy courses in 22 children with cancer were analyzed. CKMB mass and TnT concentrations were within the normal range in all children before anthracycline therapy. Within 72 hours from anthracycline therapy no increment of one of these two marker proteins was detected (ANOVA for repeated measures, P = 0.94 [TnT] and 0.25 [CKMB]). We conclude that only minimal if any acute necroses of cardiac myocytes occur after anthracycline therapy. Even membrane integrity appears to be maintained within the first 3 days after anthracycline therapy, in the absence of electrocardiographic or echocardiographic signs of acute cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623727     DOI: 10.1002/mpo.2950250305

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

Review 1.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

2.  Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia.

Authors:  Antonio Ruggiero; Gabriella De Rosa; Daniela Rizzo; Andrea Leo; Palma Maurizi; Alessia De Nisco; Francesca Vendittelli; Cecilia Zuppi; Alvaro Mordente; Riccardo Riccardi
Journal:  Int J Clin Oncol       Date:  2012-08-22       Impact factor: 3.402

Review 3.  Cardiovascular disease in survivors of hematopoietic cell transplantation.

Authors:  Saro H Armenian; Eric J Chow
Journal:  Cancer       Date:  2013-10-25       Impact factor: 6.860

Review 4.  Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.

Authors:  Joseph A Sparano; David L Brown; Antonio C Wolff
Journal:  Drug Saf       Date:  2002       Impact factor: 5.228

5.  Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.

Authors:  Saro H Armenian; Sarah K Gelehrter; Eric J Chow
Journal:  Cardiol Res Pract       Date:  2012-08-15       Impact factor: 1.866

6.  Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.

Authors:  F J F Broeyer; S Osanto; H J Ritsema van Eck; A Q M J van Steijn; B E P B Ballieux; R C Schoemaker; A F Cohen; J Burggraaf
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-15       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.